新聞發佈室

同覓瑞與時俱進

專題稿

新聞發佈

隨著我們不斷創新與發展科學技術、將新型產品推向市場,及時了解我們的最新消息和活動。- 立足新加坡,服務全世界。

15 February 2022

MiRXES announced today the set-up of its Hong Kong office and the appointment of Mr. Martin LAW as Managing Director in Hong Kong, who will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU. Mr. Law will lead the establishment and operations of MiRXES Hong Kong Limited, to explore partnerships in providing accurate, affordable and accessible cancer early detection to the Hong Kong and Greater Bay Area communities.

22 November 2021

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

15 November 2021

MiRXES announced today the appointment of Mr. Dan HEADON as Senior Vice President (SVP), Marketing. Mr. Headon will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products.

23 October 2021

Yayasan MENDAKI and MiRXES , are pleased to announce today the setting up of the “MENDAKI – MIRXES Scholarship” for Malay/Muslim students who are pursuing undergraduate and post-graduate studies in Life and Biomedical Sciences. In addition to the scholarships, the students will also receive internship opportunities and securing employment opportunities with MiRXES upon their graduation.

1 October 2021

MiRXES announced today the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products.

21 September 2021

MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.

20 September 2021

MiRXES announced today the appointment of Dr. David CAPES as Senior Vice President and Global Head of Innovation. In this newly created role, Dr. Capes will focus on the transformation of MIRXES from a regional SME to a global innovation enterprise over the next three years.
Dr Holger Heyn

28 July 2021

Dr. Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics.
PCR Lab

8 July 2021

This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.

24 February 2021

This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.

媒體報道

閱讀我們的媒體新聞,了解最新動態。

2 Feb 2022

Portfolio – If Dr. Zhou Lihan had his way, preventive healthcare, more particularly, the early diagnosis of cancer using fuss-free cancer tests, even when no symptoms are displayed, would be the driving force of the medical field in the future. It’s a noble cause and one that’s deeply personal.

6 Dec 2021

Singapore Business Review – MiRXES won two trophies at the 2021 SBR Management Excellence Awards. The company was awarded the Team of the Year trophy while MiRXES Co-founder and CEO, Dr. Zhou Lihan was named Executive of the Year for Biotechnology.

合作

我們的合作夥伴

15 Sep 2021

ヒューマン・メタボローム・テクノロジーズ株式会社 代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。

31 Aug 2021

大阪国際がんセンター(以下、当センター)は、希少疾患の一つである成人T細胞白血病リンパ腫※1(以下、ATL)のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。

洞察力

歡迎使用我們站在生物技術產業前沿的知見深邃的知識庫。

Congratulations to Associate Professor Too Heng-Phon from the Department of Biochemistry and NUS Centre for Cancer Research at NUS Medicine, who has been conferred the President’s Technology Award 2021.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.

媒體和投資者聯絡人

媒體垂詢請發郵件至:communications@mirxes.com

投資者查詢,請電郵: investors@mirxes.com

版權所有©2022 MiRXES Pte Ltd. 保留所有權利。| 私隱政策
Scroll to Top